南京瑞初医药

Redearly Bio is a Nanjing-based biotechnology company dedicated to the discovery and development of innovative therapies for aging-related diseases. Founded in 2021, the company focuses on the biological mechanisms of aging, such as cellular senescence and metabolic dysfunction, to address unmet medical needs in chronic conditions. Their proprietary platform integrates systematic aging research with drug screening to identify novel small molecule candidates. Redearly Bio's lead programs, including RE001 and RE002, target metabolic and degenerative disorders driven by the aging process. The company has successfully secured significant early-stage funding from prominent investors like Qiming Venture Partners to accelerate its pre-clinical pipeline.